Rigel Pharmaceuticals (RIGL) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Rigel Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$179.28M

Latest Revenue (Q)

$55.31M

Main Segment (Y)

Gross product sales

Rigel Pharmaceuticals Revenue by Period

Rigel Pharmaceuticals Revenue by Year

Date	Revenue	Change
2024-12-31	$179.28M	53.38%
2023-12-31	$116.88M	-2.79%
2022-12-31	$120.24M	-19.43%
2021-12-31	$149.24M	37.39%
2020-12-31	$108.62M	83.21%
2019-12-31	$59.29M	33.20%
2018-12-31	$44.51M	892.62%
2017-12-31	$4.48M	-78.00%
2016-12-31	$20.38M	-29.46%
2015-12-31	$28.89M	250.24%
2014-12-31	$8.25M	15.38%
2013-12-31	$7.15M	217.78%
2012-12-31	$2.25M	-52.63%
2011-12-31	$4.75M	-96.20%
2010-12-31	$125.00M	16566.67%
2009-12-31	$750.00K	100.00%
2008-12-31	-	-100.00%
2007-12-31	$12.60M	-62.36%
2006-12-31	$33.47M	102.55%
2005-12-31	$16.53M	249.17%
2004-12-31	$4.73M	-57.19%
2003-12-31	$11.05M	-29.98%
2002-12-31	$15.79M	3.17%
2001-12-31	$15.30M	15.77%
2000-12-31	$13.22M	47.13%
1999-12-31	$8.98M	-

Rigel Pharmaceuticals generated $179.28M in revenue during NA 2024, up 53.38% compared to the previous quarter, and up 302.38% compared to the same period a year ago.

Rigel Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$55.31M	50.12%
2024-06-30	$36.84M	24.74%
2024-03-31	$29.53M	-17.48%
2023-12-31	$35.79M	27.22%
2023-09-30	$28.13M	4.64%
2023-06-30	$26.89M	3.13%
2023-03-31	$26.07M	-49.16%
2022-12-31	$51.28M	128.82%
2022-09-30	$22.41M	-24.85%
2022-06-30	$29.82M	78.18%
2022-03-31	$16.73M	-18.00%
2021-12-31	$20.41M	-5.26%
2021-09-30	$21.54M	-17.98%
2021-06-30	$26.27M	-67.58%
2021-03-31	$81.02M	339.12%
2020-12-31	$18.45M	0.33%
2020-09-30	$18.39M	14.78%
2020-06-30	$16.02M	-71.27%
2020-03-31	$55.76M	262.08%
2019-12-31	$15.40M	-26.16%
2019-09-30	$20.86M	100.41%
2019-06-30	$10.41M	-17.56%
2019-03-31	$12.62M	-66.65%
2018-12-31	$37.86M	678.15%
2018-09-30	$4.87M	172.24%
2018-06-30	$1.79M	100.00%
2018-03-31	-	100.00%
2017-12-31	-	-100.00%
2017-09-30	$900.00K	100.00%
2017-06-30	-	-100.00%
2017-03-31	$3.58M	19.47%
2016-12-31	$3.00M	-20.21%
2016-09-30	$3.76M	-56.25%
2016-06-30	$8.59M	70.89%
2016-03-31	$5.03M	-41.09%
2015-12-31	$8.54M	-34.31%
2015-09-30	$13.00M	150.69%
2015-06-30	$5.18M	138.02%
2015-03-31	$2.18M	-73.60%
2014-12-31	$8.25M	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	-100.00%
2013-12-31	$5.75M	100.00%
2013-09-30	-	-100.00%
2013-06-30	$1.40M	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	-100.00%
2012-06-30	$1.50M	100.00%
2012-03-31	$750.00K	100.00%
2011-12-31	-	-100.00%
2011-09-30	$4.36M	1002.53%
2011-06-30	$395.00K	100.00%
2011-03-31	-	100.00%
2010-12-31	-	-100.00%
2010-09-30	$72.28M	46.15%
2010-06-30	$49.46M	1416.62%
2010-03-31	$3.26M	334.80%
2009-12-31	$750.00K	100.00%
2009-09-30	-	100.00%
2009-06-30	-	100.00%
2009-03-31	-	100.00%
2008-12-31	-	100.00%
2008-09-30	-	100.00%
2008-06-30	-	100.00%
2008-03-31	-	-100.00%
2007-12-31	$8.00M	-

Rigel Pharmaceuticals generated $55.31M in revenue during Q3 2024, up 50.12% compared to the previous quarter, and up 205.71% compared to the same period a year ago.

Rigel Pharmaceuticals Revenue Breakdown

Rigel Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Discounts and allowances	$-65.02M	$-42.76M	$-31.80M	$-18.18M	-
Gross product sales	$209.92M	$147.06M	$108.52M	$81.19M	-
License	$14.00M	$40.36M	-	-	-
Contract revenues from collaborations	$34.38M	$39.02M	$75.73M	-	-
Product sales, net	$144.90M	$104.29M	$76.72M	$63.01M	-
Government contracts	-	$1.10M	-	-	-
Milestone	-	$75.00K	-	-	-
Revenues from collaborations	-	$11.49M	-	-	-
Research and development services and others	-	-	$6.09M	$3.30M	-
Development milestones	-	-	$25.00M	$1.88M	-
Government contract	-	-	$4.50M	$10.50M	-
License revenues	-	-	$7.93M	$70.55M	-
Gross Product	-	-	-	-	$76.47M
Discounts And Allowances	-	-	-	-	$-14.77M
Development Milestones	-	-	-	-	$2.10M
Contract Revenues From Collaborations	-	-	-	-	$46.92M
Research And Development Services And Others	-	-	-	-	$4.47M
Product	-	-	-	-	$61.70M

Rigel Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Gross product sales (62.07%), Product sales, net (42.85%), Contract revenues from collaborations (10.17%), License (4.14%), and Discounts and allowances (-19.23%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Product sales, net	$79.97M	$38.93M	$26.00M	$56.67M	$23.88M	$23.75M	$22.78M	$19.19M	$18.55M	$16.20M	$17.57M	-	-	-	-	-	-	-	-	-
License	$4.00M	$10.00M	$2.43M	$3.31M	$64.62M	$-1.60M	$2.10M	-	$39.86M	$-3.55M	$7.75M	-	-	-	-	-	-	-	-	-
Gross product sales	$115.18M	$56.32M	$38.43M	$80.40M	$33.46M	$33.20M	$32.50M	$26.98M	$26.43M	$22.62M	$22.49M	-	-	-	-	-	-	-	-	-
Discounts and allowances	-	$-17.39M	$-12.42M	-	$-9.57M	$-9.45M	$-9.72M	$-7.79M	$-7.88M	$-6.42M	$-4.92M	-	-	-	-	-	-	-	-	-
Revenues from collaborations	-	$16.38M	$3.53M	$722.00K	$11.27M	$538.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contract revenues from collaborations	-	-	-	-	$2.00M	$2.33M	$26.50M	$1.84M	-	-	-	-	-	-	-	-	-	-	-	-
Government contract	-	-	-	-	$1.00M	$2.00M	$2.50M	$1.00M	-	-	-	-	-	-	-	-	-	-	-	-
Research and development services and others	-	-	-	-	-	-	$1.11M	$722.00K	$3.93M	$330.00K	$1.64M	-	-	-	-	-	-	-	-	-
Development milestones	-	-	-	-	-	-	$20.00M	-	$5.00M	-	-	-	-	-	-	-	-	-	-	-
License revenues	-	-	-	-	-	-	$5.39M	-	$2.34M	$208.00K	$199.00K	-	-	-	-	-	-	-	-	-
Contract Revenues From Collaborations	-	-	-	-	-	-	-	-	-	-	-	$4.53M	$3.71M	$65.64M	$697.00K	$2.10M	$1.05M	$43.08M	$1.57M	$9.14M
Research And Development Services And Others	-	-	-	-	-	-	-	-	-	-	-	$225.00K	$408.00K	$1.02M	$197.00K	-	$1.05M	$3.22M	$-376.00K	$1.39M
Product	-	-	-	-	-	-	-	-	-	-	-	$16.01M	$17.05M	$12.38M	$17.75M	$16.29M	$14.97M	$12.68M	$13.83M	$11.72M
Gross Product	-	-	-	-	-	-	-	-	-	-	-	$20.55M	$22.04M	$16.11M	$22.43M	$20.32M	$18.35M	$15.37M	$16.34M	$14.35M
Government Contract	-	-	-	-	-	-	-	-	-	-	-	$1.00M	$5.50M	$3.00M	-	-	-	-	-	-
Discounts And Allowances	-	-	-	-	-	-	-	-	-	-	-	$-4.53M	$-4.98M	$-3.73M	$-4.67M	$-4.03M	$-3.38M	$-2.69M	$-2.51M	$-2.63M
Development Milestones	-	-	-	-	-	-	-	-	-	-	-	$1.88M	-	-	-	-	-	-	-	-

Rigel Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Gross product sales (57.83%), Product sales, net (40.16%), and License (2.01%).

Rigel Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RIGL	Rigel Pharmaceuticals	$179.28M	$55.31M
DAWN	Day One Biopharmaceuticals	$131.16M	$20.07M
FBIO	Fortress Biotech	$55.13M	$14.63M
XFOR	X4 Pharmaceuticals	$2.56M	$560.00K
CDTX	Cidara Therapeutics	$1.27M	-
IMMX	Immix Biopharma	-	-
RVPH	Reviva Pharmaceuticals	-	-
ZURA	Zura Bio	-	-
ABOS	Acumen Pharmaceuticals	-	-
INZY	Inozyme Pharma	-	-
LPTX	Leap Therapeutics	-	-
TERN	Terns Pharmaceuticals	-	-
ELEV	Elevation Oncology	-	-
ENVB	Enveric Biosciences	-	-
MREO	Mereo BioPharma Group	-	-

RIGL Revenue FAQ

What is Rigel Pharmaceuticals’s yearly revenue?

Rigel Pharmaceuticals's yearly revenue for 2024 was $179.28M, representing an increase of 53.38% compared to 2023. The company's yearly revenue for 2023 was $116.88M, representing a decrease of -2.79% compared to 2022. RIGL's yearly revenue for 2022 was $120.24M, representing a decrease of -19.43% compared to 2021.

What is Rigel Pharmaceuticals’s quarterly revenue?

Rigel Pharmaceuticals's quarterly revenue for Q3 2024 was $55.31M, a 50.12% increase from the previous quarter (Q2 2024), and a 96.58% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $36.84M, a 24.74% increase from the previous quarter (Q1 2024), and a 37.03% increase year-over-year (Q2 2023). RIGL's quarterly revenue for Q1 2024 was $29.53M, a -17.48% decrease from the previous quarter (Q4 2023), and a 13.29% increase year-over-year (Q1 2023).

What is Rigel Pharmaceuticals’s revenue growth rate?

Rigel Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 49.10%, and for the last 5 years (2020-2024) was 65.05%.

What are Rigel Pharmaceuticals’s revenue streams?

Rigel Pharmaceuticals's revenue streams in c 24 are Discounts and allowances, Gross product sales, License, Contract revenues from collaborations, and Product sales, net. Discounts and allowances generated $-65.022M in revenue, accounting -19.23% of the company's total revenue, up 52.05% year-over-year. Gross product sales generated $209.92M in revenue, accounting 62.07% of the company's total revenue, up 42.75% year-over-year. License generated $14M in revenue, accounting 4.14% of the company's total revenue, down -65.31% year-over-year. Contract revenues from collaborations generated $34.38M in revenue, accounting 10.17% of the company's total revenue, down -11.91% year-over-year. Product sales, net generated $144.9M in revenue, accounting 42.85% of the company's total revenue, up 38.94% year-over-year.

What is Rigel Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Rigel Pharmaceuticals was Gross product sales. This segment made a revenue of $209.92M, representing 62.07% of the company's total revenue.